Case ReportsAspergillus flavus Left Ventricular Assist Device Driveline Exit Site InfectionCunningham, Hayley E. MD∗; Tessmann, Paul B. MD, PharmD†; Lachiewicz, Anne M. MD, MPH‡Author Information From the ∗Department of Internal Medicine, Duke University Health System, Durham †Division of Cardiothoracic Surgery ‡Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC. Correspondence to: Anne M. Lachiewicz, MD, MPH, Division of Infectious Diseases, University of North Carolina, 130 Mason Farm Rd, CB 7030, Chapel Hill, NC 27599-7030. E-mail: firstname.lastname@example.org. A.M.L. has served as a consultant for MicrogenDx and Shionogi. The remaining authors of this article have no conflicts of interest to disclose, including financial interests, activities, relationships, or affiliations. Infectious Diseases in Clinical Practice: March 2020 - Volume 28 - Issue 2 - p 99-101 doi: 10.1097/IPC.0000000000000808 Buy Metrics AbstractIn Brief Infection is a leading cause of death after left ventricular assist device implantation, but mold infections are rare. We present a unique case of localized Aspergillus left ventricular assist device driveline exit site infection successfully treated with debridement, antifungal therapy, and device retention, but the course was complicated by emergence of triazole resistance. Infection is a leading cause of death following left ventricular assist device (LVAD) implantation, but mold infections are rare. The authors describe what is, to their knowledge, the first reported case of an ambulatory patient with LVAD-associated Aspergillus infection successfully treated in an outpatient setting with debridement, antifungal therapy, and device retention. His treatment course was complicated by emergence of triazole-resistance, which is becoming surprisingly more frequent, even among patients without severe immunocompromising conditions. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.